Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
REGULATORY
Govt Presents Growth Strategy Draft Ahead of July Approval
The Japanese government on June 30 presented a draft of its growth strategy, mapping out plans to expand public-private investments across 17 strategic sectors, including drug discovery and advanced medicine, ahead of Cabinet approval expected later in July. The strategy,…
To read the full story
Related Article
- Japan OKs Honebuto, Growth Strategy with Patented Drug Market Goals
July 21, 2026
- EFPIA Urges Global-Level Launch Prices, Patent-Term Price Protection
June 26, 2026
- Shionogi Welcomes Government Roadmap’s Focus on Infectious Diseases
June 26, 2026
- Japan Targets Global-Level Growth for Domestic Patented Drug Market
June 25, 2026
- Industry Hails Japan Growth Roadmap, PhRMA Urges Follow-Through
June 25, 2026
- Official Hints at Potential Change to Growth Target in Draft Roadmap
June 11, 2026
- MHLW Official Says US MFN Policy Could Be Taken Up by Chuikyo
May 15, 2026
- Pfizer Japan Chief Urges Applying 9.6% Growth Target to Domestic Market
April 7, 2026
- Council Floats 9.6% Growth Goal for Global Patented Drug Sales by Japan Pharma
March 11, 2026
REGULATORY
- MOF Presses for Full FY2027 Drug Price Revision Without Price Gap Thresholds
November 4, 2026
- Japan Panel to Review Kyowa Kirin’s Libmeldy for Approval on Nov. 9
November 4, 2026
- PMDA Sets Out AI Principles for Regulatory Activities, Stresses Human Oversight
November 4, 2026
- Public-Private Pharma Talks Expand to Domestic R&D, Manufacturing Investment
November 2, 2026
- Japan’s Healthcare Spending Hits Record 48.8 Trillion Yen in FY2024
November 2, 2026
Analysis of individual placements across 43 companies over the past 18 months paints a vivid picture of Japan’s evolving healthcare industry. This comprehensive snapshot illuminates current market demands, strategic shifts, and the enduring appeal of this pivotal Asian market.Rare Diseases…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Japan’s pharmaceutical industry asked the ruling Liberal Democratic Party (LDP) on October 29 to boost the country’s drug supply security…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…